Twist Bioscience underperformed the market so far this year, based on data from August 4, 2025.
2 reports, 2 independent
Updated Aug 1
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Twist Bioscience underperformed the market so far this year, based on data from August 4, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Twist Bioscience and OmniAb are competing in the synthetic DNA products market.1 source
Twist Bioscience underperformed the market so far this year.1 source
Keep exploring
The entities involved
-
Twist Bioscience
Biotechnology company
- Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.
- VUG concentrates on large-cap leaders like Nvidia. VUG holds large-cap leaders such as Microsoft. VUG holds established giants including Apple. IWO holds small-cap equities including Twist Bioscience.
Related events
Coverage
Newest first; wire copies grouped- themarketsdaily.com
- ZacksTwist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates Twist Bioscience (TWST) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.54. This